The U.S. Food and Drug Administration approved Immunocore’s Kimmtrak (tebentafusp-tebn) for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma (mUM).
Bay Area-based CytomX and Astellas forged a strategic relationship worth up to more than $1.6 billion to discover and develop novel T-cell engaging bispecific antibodies targeting CD3 and tumor cell surface antigens for the treatment of cancer.
GO Therapeutics, with headquarters in Cambridge, Mass., signed a licensing deal with Swiss-based Roche to develop antibodies for cancer.
Amgen Inc. and The University of Texas MD Anderson Cancer Center announced two multi-year collaborative research deals for a broad range of cancer therapeutics. The cancers studied will include leukemia, myelodysplastic syndromes (MDS), multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies.